Expert Interview
A Second Look: Discussing the new data available from ASH 2023 with a focus on Arcellx’s Phase 1 Study of Anito-cel in patients with relapsed or refractory multiple myeloma
Ticker(s): ACLX- Hem / Onc in private practice. 10 years of experience.
- Academic hem malignancy expertise at a major NCCN center.
- An ad hoc reviewer for Medicine, Science Translational Medicine, Blood, Hematologica , and Lancet Haematology.
- Adjunct Associate Professor in the Department of Medicine at Johns Hopkins University School of Medicine
- A clinician, researcher, and educator practicing oncology, benign and malignant hematology with a focus on the lymphoid malignancies, including chronic lymphocytic leukemia (CLL), lymphoma, myeloma, AL amyloidosis, as well as bone marrow transplant.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
